Trovafoxacin Potentiation of Lipopolysaccharide-Induced Tumor Necrosis Factor Release from RAW 264.7 Cells Requires Extracellular Signal-Regulated Kinase and c-Jun N-Terminal Kinase

Kyle L. Poulsen, Ryan P. Albee, Patricia E. Ganey, and Robert A. Roth

Department of Pharmacology & Toxicology, Center for Integrative Toxicology, Michigan State University, East Lansing, Michigan

Received November 13, 2013; accepted February 11, 2014

ABSTRACT

Trovafoxacin (TVX) is a fluoroquinolone antibiotic known to cause idiosyncratic, drug-induced liver injury (IDILI) in humans. The mechanism underlying this toxicity remains unknown. Previously, an animal model of IDILI in mice revealed that TVX synergizes with inflammatory stress from bacterial lipopolysaccharide (LPS) to produce a hepatotoxic interaction. The liver injury required prolongation of the appearance of tumor necrosis factor-α (TNF) in the plasma. The results presented here describe a model of TVX/LPS coexposure in RAW 264.7 cells acting as a surrogate for TNF-releasing cells in vivo. Pretreating cells with TVX for 2 hours before LPS addition led to increased TNF protein release into culture medium in a concentration- and time-dependent manner relative to cells treated with LPS or TVX alone. During the pretreatment period, TVX increased TNF mRNA, but this was less apparent when cells were exposed to TVX after LPS addition, suggesting that the pivotal signaling events that increase TNF expression occurred during the TVX pretreatment period. Indeed, TVX exposure increased activation of extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and p38 mitogen-activated protein kinase. Inhibition of either ERK or JNK decreased the TVX-mediated increase in TNF mRNA and LPS-induced TNF protein release, but p38 inhibition did not. These results demonstrated that the increased TNF appearance from TVX-LPS interaction in vivo can be reproduced in vitro and occurs in an ERK- and JNK-dependent manner.

Introduction

Drug-induced liver injury (DILI) is responsible for more than half of acute liver failure cases in the United States (Ostapowicz et al., 2002). DILI is associated with significant morbidity and mortality. It is the most common adverse effect that prevents market approval for new drug entities, and it prompts removal of efficacious drugs from the market (Watkins, 2005). An important subset of DILI is idiosyncratic, drug-induced liver injury (IDILI), which accounts for 13% of all cases of acute liver failure (Ostapowicz et al., 2002). Although this represents a fraction of all instances of DILI, the bulk of Food and Drug Administration-imposed restrictions on the use of drugs is due to idiosyncratic adverse drug reactions (Lasser et al., 2002).

Causes of IDILI are not well understood. Among several hypotheses put forth to explain IDILI is the inflammatory stress hypothesis, which states that a mild inflammatory episode interacts with a drug, resulting in hepatotoxicity (Shaw et al., 2010). Animal models based on this hypothesis have been developed for several drugs that have caused IDILI in humans, including chlorpromazine, ranitidine, amiodarone, doxorubicin, sulindac, and trovafloxacin (TVX) (Buchweitz et al., 2002; Luyendyk et al., 2003; Shaw et al., 2007; Hassan et al., 2008; Zou et al., 2009; Lu et al., 2012). In each of these models, bacterial lipopolysaccharide (LPS) was used to cause a modest, nontoxic, acute inflammatory episode.

Binding of LPS to Toll-like receptor 4 on inflammatory cells leads to activation of proximal intracellular signaling factors in the MyD88 (myeloid differentiation primary response 88)-dependent pathway (Chow et al., 1999). The result is intracellular signaling that activates canonical mitogen-activated protein kinases (MAPKs), including extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and p38 (Reimann et al., 1994; Sanghera et al., 1996; Swantek et al., 1997). Activated MAPKs induce the transactivation of genes that encode tumor necrosis factor-α (TNF) and other mediators of acute inflammation, as well as increase the stability of TNF mRNA (Wang et al., 2001; DeLeaut et al., 2008). TNF has been

This study was supported by National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases [Grant DK0861315] and National Institutes of Health National Institute of Environmental Health Sciences [Training Grant T32ES007255 (to K.L.P.)].

dx.doi.org/10.1124/jpet.113.211276.

This article has supplemental material available at jpet.aspetjournals.org.

ABBREVIATIONS: ATF2, activating transcription factor 2; CPZ, chlorpromazine; DMEM, Dulbecco’s modified Eagle’s medium; DILI, drug-induced liver injury; ERK, extracellular signal-regulated kinase; FBS, fetal bovine serum; IDILI, idiosyncratic drug-induced liver injury; JNK, c-Jun N-terminal kinase; KC, Kupffer cell; LPS, lipopolysaccharide; LVX, levofloxacin; MAPK, mitogen-activated protein kinase; MAPKAPK-2, MAPK-activated protein kinase 2; NF-κB, nuclear factor κ-light-chain-enhancer of activated B cells; PCR, polymerase chain reaction; SAL, saline; SB203580, 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole; SP600125, 1,9-pyrazoloanthrone; TNF, tumor necrosis factor-α; TVX, trovafloxacin; U0126, 1,4-diamo-2,3-dicyano-1,4-bis[2-aminophenylthio] butadiene; VEH, vehicle.
implicated as a critical mediator of liver injury in drug-LPS cotreatment models using several of the aforementioned IDILI-associated drugs.

TVX is a broad-spectrum antibiotic in the fluoroquinolone class that acts by inhibiting bacterial DNA gyrase and topoisomerase IV (Brighty and Gootz, 1997). Soon after its introduction into the market, TVX use was severely restricted due to 14 cases of acute liver failure, of which six were fatal (Ball et al., 1999). An animal model of TVX IDILI was established in which mice coexposed to nontoxic doses of TVX and LPS developed pronounced hepatocellular injury (Shaw et al., 2007). A defining characteristic of this model was that the liver injury depended upon TNF. Pharmacological intervention with pentoxifylline to inhibit TNF transcription or with etanercept to neutralize released TNF prevented the injury (Shaw et al., 2007). Studies in TNF receptor knockout mice supported a key role for TNF in TVX/LPS hepatotoxicity (Shaw et al., 2009b).

Importantly, the LPS-induced increase in plasma concentration of TNF was significantly prolonged by TVX, and this prolongation proved to be critical in the pathogenesis of liver injury. In animals treated with TVX and TNF rather than LPS, liver injury also occurred, and TVX caused the appearance of TNF in plasma to be prolonged due in part to enhanced TNF synthesis (Shaw et al., 2009a). Whether this resulted from a direct effect on TNF-producing cells was unknown. Accordingly, the purpose of the present study was to test the hypothesis that TVX pretreatment directly increases LPS-induced TNF synthesis and release by cells in vitro and to explore the underlying intracellular signaling involved in the response.

**Materials and Methods**

**Chemicals and Inhibitors.** All chemicals and reagents in this study were purchased from Sigma-Aldrich (St. Louis, MO) unless stated otherwise. Antibiotic/antimycotic and Dulbecco's modified Eagle's medium (DMEM) were purchased from Life Technologies (Grand Island, NY).

**Cell Culture.** The RAW 264.7 macrophage cell line (American Type Culture Collection, Manassas, VA) was maintained in DMEM supplemented with 10% heat-inactivated fetal bovine serum (FBS) and 1% antibiotic/antimycotic at 37°C in 5% CO2. Cells were harvested by detachment with a sterile spatula and plated at a density of 4 × 10^4 cells per well in 24-well plates (Costar, Lowell, MA) for cytokine release and RNA isolation or 1 × 10^6 cells per well in 10-cm plates (Costar) for protein isolation. Medium was replaced after 24 hours with DMEM (0.5% FBS) for cell synchronization prior to drug exposure 16 hours later.

**TNF Release.** Synchronized RAW 264.7 cells, at 80–90% confluence, were pretreated for 2 hours with various concentrations of TVX (0–100 μM) in 0.5% fetal bovine serum–containing medium. TVX was dissolved in 0.1 N potassium hydroxide (vehicle (VEH)) at a stock concentration of 50 mM and diluted to the final concentration in 0.5% fetal bovine serum–containing medium. This 2-hour incubation was followed by a change to medium containing LPS from *Escherichia coli* serotype O55:B5 (lot 075K4038) at various concentrations (0.1–100 ng/ml) or saline vehicle (SAL) as control. The LPS had an activity of 3.3 × 10^6 endotoxin units/ml as determined using a chromogenic, *Liluus* amebocyte lysate assay (Kit 50-650U; Cambrex Corp., East Rutherford, NJ). For determination of TNF release, an enzyme-linked immunosorbent assay (ELISA) was performed (BD Biosciences, San Jose, CA). Cell culture medium was withdrawn at various times and stored at −20°C until the time of analysis. Ninety-six–well plates were coated with an anti-TNF capture antibody in a coating buffer overnight at 4°C. Medium was diluted to remain within standard curve concentrations.

**Protein Isolation.** RAW 264.7 cells seeded in 10-cm plates as previously stated were exposed to TVX or an equivalent volume of VEH. At the indicated times, plates were washed twice with ice-cold phosphate-buffered saline and scraped with 1 ml of ice-cold phosphate-buffered saline. The cells were pelleted (400g for 2 minutes) and then resuspended in ice-cold radioimmunoprecipitation assay buffer (Thermo Fisher Scientific, Rockford, IL) supplemented with serine protease inhibitor phenylmethylsulfonyl fluoride and HALT protease and phosphatase inhibitor cocktails (Thermo Fisher Scientific). After a 10-minute incubation on ice, suspended pellets were sonicated twice with 5-second pulses. Suspensions were centrifuged at 22,000g for 30 minutes, and supernatants were withdrawn and stored at −80°C until analysis occurred.

**Nuclear Factor κB Activation.** Activation of nuclear factor κB (NF-κB) was assessed from the binding of the p65 subunit to DNA using a TransAm NF-κB Transcription Factor ELISA Kit (ActiveMotif, Carlsbad, CA). Nuclear extracts of RAW cells were prepared per the manufacturer’s instructions. Extracts were then incubated in a 96-well plate coated with an oligonucleotide sequence that corresponds to the consensus binding element NF-κB. After incubation with the extract, an antibody directed against an epitope of the p65 subunit of NF-κB was added. A secondary antibody was added that detects the primary antibody-bound p65. Finally, a developing solution was added, and p65 binding was assessed colorimetrically by measuring the optical density at 450 nm; background optical density was subtracted from all groups.

**Western Analysis.** Protein concentration in extracts was determined by bicinchoninic acid assay (Thermo Fisher Scientific). All western analyses were performed by loading 20 μg of protein on precast NuPAGE SDS-PAGE gels (Life Technologies) using all NuPAGE reagents. For phospho-MAPK, samples were separated on precast 12% gels. After separation, proteins were transferred to polyvinylidene difluoride membranes (Millipore, Billerica, MA) for 1 hour at 4°C. Membranes were blocked in 5% bovine serum albumin dissolved in Tris-buffered saline plus 0.1% Tween 20, and membranes were washed for 30 minutes in Tris-buffered saline plus 0.1% Tween 20, and blocked prior to incubation with antibodies to total ERK, ATF, p38, or lamin B1.

**RNA Isolation and Reverse Transcription-Polymerase Chain Reaction.** Total RNA was isolated using TRIZol reagent (Life Technologies) per the manufacturer’s instructions. RNA quantity and quality were assessed using Nanodrop 2000 (Thermo Fisher Scientific). cDNA was prepared using 1 μg of RNA with the iScript cDNA synthesis kit (Bio-Rad Laboratories, Hercules, CA). The expression of specific genes was analyzed using SYBR Green (Applied Biosystems, Foster City, CA). Expression level was normalized to β-actin. Polymerase chain reaction (PCR) primers used were as follows: mouse TNF [5′-TCTCATGCACCACCATCAGGACT-3′ (forward) and 5′-ACCACCTCCCTTGTTAGAAGACTA-3′ (reverse)] and mouse β-actin [5′-TGAGTAGTGGAGAAGTTGTCAGAA-3′ (forward) and 5′-TGTGGTGCCAGATCTCCATGT-3′ (reverse)].

**Statistical Analysis.** A one- or two-way analysis of variance was performed on data sets with Tukey’s post-hoc test applied for multiple comparisons between groups. The criterion for significance was P < 0.05.

**Results**

Trovafloxacin Pretreatment Potentiates LPS-Induced TNF Release in a Dose- and Time-Dependent Manner. In mice, the maximal hepatotoxic response to TVX occurred when the animals were treated with TVX 3 hours before LPS...
exposure (Shaw et al., 2007). To approximate this exposure in vitro, RAW cells were exposed to TVX prior to LPS using the regimen depicted in Fig. 1. It is important to note that the TVX-LPS interaction described below required pretreatment with TVX followed by removing the TVX-containing medium and replacing it with medium containing LPS.

Exposure of cells for 6 hours to LPS (0.1–100 ng/ml) by itself resulted in a concentration-dependent increase in TNF concentration in the culture medium (Fig. 2A). Pretreatment with TVX (1, 10, or 100 μM) significantly increased LPS-induced TNF release in a concentration-dependent manner. The maximal difference between VEH- and TVX-pretreated cells was detected with a combination of 100 μM TVX and 10 ng/ml LPS, so further studies were conducted using this combination. Levofloxacin (LVX), a quinolone antibiotic used as a negative comparator because of its lesser association with IDILI, did not significantly increase TNF release 6 hours after LPS exposure (Fig. 2B). This is consistent with previous results in mice treated with LVX/LPS (Shaw et al., 2007).

TVX pretreatment increased LPS-induced TNF release into cell culture medium at all times (1–10 hours) after LPS exposure (Fig. 3). TVX pretreatment also increased TNF release into the medium in SAL-treated cells at all times observed, although the increase was small. In cells treated only with LPS, the rate of TNF release (i.e., slope of lines in Fig. 3) was greatest from 1 to 3 hours and decreased thereafter. In comparison, the release rate in LPS-TVX-cotreated cells was greater from 1 to 3 hours and remained constant through 6 hours (Table 1). TVX pretreatment also increased the rate of release in the absence of LPS.

TVX, but Not LVX, Significantly Increases TNF mRNA Prior to LPS Addition. TVX pretreatment of RAW cells did not increase TNF mRNA from 1 to 3 hours after SAL or LPS exposure despite the consistent increases in TNF protein release, although a trend was observed (Supplemental Fig. 1). Accordingly, the effect of TVX on TNF mRNA prior to LPS addition was assessed. Exposure of RAW cells to TVX for 2 hours increased TNF mRNA (Fig. 4). In contrast, exposure to LVX for 2 hours failed to affect TNF mRNA (Supplemental Fig. 2).

TVX Treatment Increases MAPK Phosphorylation Prior to LPS Addition, and ERK and JNK Signaling Are Required for TVX-Mediated Increases in LPS-Induced TNF Release. These results indicated that pivotal changes in signaling that led to increased TNF mRNA occurred during the TVX pretreatment, so the next studies investigated MAPK activation during this period. MAPK activation can increase TNF mRNA in inflammatory cells (reviewed in Guha and Mackman, 2001). Accordingly, the role of ERK, JNK, and p38 in TNF mRNA induction was assessed in TVX-treated RAW cells. ERK phosphorylation was increased after 1 hour, but not after 2 hours, of TVX exposure (Fig. 5A). The selective MEK1 (MAPK or Erk kinase 1) inhibitor and ERK-activation inhibitor, U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-amino-phenylthio] butadiene) (Favata et al., 1998), abolished all phospho-ERK signal, indicating a complete inhibition of ERK1/2-mediated signaling. As expected, TVX caused an increase in TNF mRNA, and U0126 prevented this increase (Fig. 5B). TNF mRNA was also decreased in VEH-pretreated cells treated with U0126. The TVX-mediated increase in LPS-induced TNF release at 3 and 6 hours was completely prevented by U0126 (Fig. 6).

Attempts were made to detect phosphorylated JNK, but despite using several different antibodies, the results were inconsistent. Instead, TVX-dependent activation of JNK was determined by phosphorylation of the known downstream target of JNK signaling, ATF2 (Fig. 5C). TVX treatment
increased phospho-ATF2 at 1 and 2 hours. The selective inhibitor of JNK activity, SP600125 (1,9-pyrazoloanthrone) (Bennett et al., 2001), markedly reduced phosphorylation of ATF2 (Fig. 5C), which suggested that the phosphorylation of ATF2 was JNK-selective. SP600125 also decreased the TVX-mediated increase in TNF mRNA (Fig. 5D). SP600125 completely prevented TVX-mediated enhancement of LPS-induced increase in TNF protein release 3 and 6 hours after LPS exposure (Fig. 6).

p38 Phosphorylation was increased 1 and 2 hours after TVX exposure (Fig. 5E). SB203580 [4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole] is a selective inhibitor of p38 activity (Cuenda et al., 1995), but it does not prevent its phosphorylation. Accordingly, the phosphorylation of MAPKAPK-2, a direct downstream target of activated p38 (Beyaert et al., 1996), was evaluated, and SB203580 markedly reduced MAPKAPK-2 phosphorylation. Despite the TVX-mediated increase in p38 phosphorylation (Fig. 5E), p38 inhibition did not reduce the TVX-induced increase in TNF mRNA (Fig. 5F). SB203580 also did not affect the TVX-induced increase in TNF protein release in the absence or presence of LPS (Fig. 6). Interestingly, SB203580 exposure during the pretreatment period decreased LPS-induced TNF release in VEH-pretreated controls at 3 and 6 hours after LPS exposure (Fig. 6).

TABLE 1
Calculated rate of change in TNF release from RAW cells

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Rate of Change in Medium TNF Concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1–3 h</td>
</tr>
<tr>
<td></td>
<td>3–6 h</td>
</tr>
<tr>
<td></td>
<td>6–10 h</td>
</tr>
<tr>
<td>VEH/SAL</td>
<td>0.66 ± 0.01</td>
</tr>
<tr>
<td></td>
<td>0.59 ± 0.02</td>
</tr>
<tr>
<td></td>
<td>0.57 ± 0.07</td>
</tr>
<tr>
<td>TVX/SAL</td>
<td>1.01 ± 0.02a</td>
</tr>
<tr>
<td></td>
<td>0.85 ± 0.04a</td>
</tr>
<tr>
<td></td>
<td>0.69 ± 0.07a</td>
</tr>
<tr>
<td>VEH/LPS</td>
<td>9.51 ± 0.14</td>
</tr>
<tr>
<td></td>
<td>6.59 ± 0.18</td>
</tr>
<tr>
<td></td>
<td>1.93 ± 0.55</td>
</tr>
<tr>
<td>TVX/LPS</td>
<td>10.55 ± 0.22b</td>
</tr>
<tr>
<td></td>
<td>10.00 ± 0.32b</td>
</tr>
<tr>
<td></td>
<td>1.04 ± 0.07b</td>
</tr>
</tbody>
</table>

*aP < 0.05 versus VEH/SAL within a time point.  
bP < 0.05 versus VEH/LPS within a time point.

Discussion

The relative infrequency with which cases of IDILI occur in humans makes elucidation of the molecular pathogenesis of IDILI difficult. That being said, several animal models of IDILI have been generated that require increased or prolonged TNF in the plasma of animals to precipitate hepatotoxicity (Shaw et al., 2007; Tukov et al., 2007; Zou et al., 2009; Lu et al., 2012). Developing a model in vitro that reproduces increased TNF production is therefore important to be able to conduct studies to understand these drug-LPS interactions in animal models of IDILI. Such a model could be used to discover previously unidentified critical molecular targets of IDILI-associated drugs in cells.

In TVX/LPS-treated mice, the drug-induced increase in LPS-stimulated TNF appearance is relatively small in magnitude, and the increased duration of plasma TNF is relatively short (Shaw et al., 2007). However, this relatively small prolongation in plasma TNF proved to be essential to the hepatotoxic TVX-LPS interaction. Etanercept given at the time of peak TNF appearance in LPS-treated mice eliminated the prolongation of TNF appearance in TVX/LPS-cotreated mice and protected them from liver injury. In contrast, etanercept administered after the TVX-mediated prolongation of plasma TNF concentration had failed to protect against the hepatocellular necrosis. Thus, the brief prolongation of TNF appearance was required for the pathogenesis of liver injury in TVX/LPS-cotreated mice (Shaw et al., 2009b). Accordingly, we sought to determine whether a similar interaction between TVX and LPS could be reproduced in TNF-producing cells in vitro.

Kupffer cells (KCs) are the largest population of fixed macrophages in the body and a likely source of TNF in response to LPS (Su et al., 2000). RAW cells were chosen as a KC surrogate because of their well characterized LPS-induced TNF production and suitability for high-throughput screening (Beutler et al., 1985). As a transformed murine macrophage, RAW cells maintain many functions ascribed to KCs and other macrophages, including cytokine release, respiratory burst and
phagocytosis, etc. TVX pretreatment increased LPS-induced TNF release in RAW cells (Figs. 2A and 3). In contrast, LVX did not, consistent with the failure of LVX to enhance LPS-mediated TNF appearance in mice (Shaw et al., 2007). Accordingly, the drug-induced increase in LPS-induced plasma TNF observed in TVX/LPS-cotreated mice was recapitulated in RAW cells in vitro.

In the time course study (Fig. 3), analysis of the rate of TNF release (Table 1) indicated that TVX-pretreated cells released TNF at a greater rate than VEH-pretreated controls through 6 hours after the addition of LPS, but not thereafter. The results suggested that the capacity to release TNF in RAW cells was nearly exhausted within 6 hours of exposure to LPS; this has been observed previously in LPS-exposed RAW cells (Rouzer et al., 2005; Wang et al., 2012). TVX pretreatment increased TNF release after removal of TVX-containing medium and replacement with LPS- or SAL-containing medium, even though TNF mRNA did not change after medium replacement (Supplemental Fig. 1). The results strongly suggest that the TVX-induced signaling that contributed to increased LPS-induced TNF mRNA occurred before the cells were exposed to LPS.

TVX treatment did increase TNF mRNA during the 2-hour drug exposure (Fig. 4). The increase in TNF mRNA occurred in a relatively short time, between 1 and 2 hours. LVX did not significantly increase TNF mRNA at this time (Supplemental Fig. 2), providing an explanation for the lack of effect of LVX on LPS-stimulated TNF appearance in vitro and in vivo (Fig. 2B; Shaw et al., 2007). LPS-induced TNF expression involves activation of NF-κB and/or MAPKs (Geppert et al., 1994; Swantek et al., 1997; Fischer et al., 1999), so these signaling proteins became a focus for investigation. Although NF-κB is a well-characterized inducer of TNF expression, TVX did not induce p65 binding to DNA before or after LPS exposure (Supplemental Fig. 3), suggesting that MAPKs are likely responsible for the TVX-mediated increase in TNF mRNA.

All three MAPKs assessed were activated during TVX pretreatment (Fig. 5, A, C, and E). ERK activation occurred early (1 hour), whereas JNK and p38 activation were increased at both times assayed (1 and 2 hours). In this initial exploration, we used selective inhibitors of each MAPK to identify which one(s) contributed to increased TNF release. TNF biosynthesis can
U0126 and SP600125 are reversible inhibitors of ERK and JNK, respectively. They were present only during the TVX pretreatment period, not during exposure to LPS. If the increase in TNF mRNA during the TVX pretreatment period was linked to TNF protein release prompted by the later exposure to LPS, then these MAPK inhibitors should reduce the TVX-mediated increase in TNF release, as observed in Fig. 6. Despite an incomplete reduction in the TVX-mediated increase in TNF mRNA prior to LPS exposure, SP600125 completely eliminated the TVX interaction with LPS. It is possible that JNK contributes to this interaction not only through increased TNF mRNA, but also through a post-transcriptional mechanism, such as increased TNF translation (Swantek et al., 1997). It is also possible that ERK and JNK both contribute to the TVX-mediated increase in TNF expression through a similar mechanism, such as increased AP-1 (activator protein 1)-dependent transactivation of the TNF gene (Chan and Riches, 1998; Cuschieri et al., 2004), but this remains a topic for future investigation.

ERK has been shown to mediate increases in TNF mRNA and protein in other models. For example, long-term ethanol treatment increases LPS-induced TNF mRNA expression and TNF protein release by macrophages in an ERK-dependent manner (Kishore et al., 2002; Pritchard and Nagy, 2005). In addition, both pro- and anti-inflammatory effects of adiponectin on LPS-induced TNF release in RAW cells are mediated through ERK-dependent signaling (Park et al., 2007; Huang et al., 2008). ERK signaling plays a significant role in experimental models of inflammatory liver injury from alcohol or biliary acid exposure (Mandrekar and Szabo, 2009; Allen et al., 2010). These results attest to the dynamic and important role ERK signaling plays in TNF biosynthesis in macrophages in models of hepatotoxicity involving inflammatory stress.

JNK has been implicated in cell-death signaling, and examples of JNK dependence in drug-inflammation interaction models of hepatocellular injury have been described (Gandhi et al., 2013; Beggs et al., 2014). Chlorpromazine (CPZ) is a phenothiazine antipsychotic drug associated with IDILI in humans, and coexposure of rats to CPZ and LPS precipitates liver injury (Buchweitz et al., 2002). Exposure of mice or primary murine hepatocytes to CPZ combined with LPS or the Toll-like receptor 2 agonist lipoteichoic acid resulted in hepatocellular injury that was associated with prolonged JNK activation (Gandhi et al., 2010). Toxicity was preceded by an increase and prolongation of TNF in the plasma of CPZ-LPS or CPZ-lipoteichoic acid coexposed animals, raising the possibility of a link between prolonged plasma TNF and hepatotoxicity, similar to what is observed during TVX-LPS coexposure. Another recent study described JNK-dependent cytotoxicity resulting from TVX/TNF coexposure in a hepatocyte cell line (Beggs et al., 2014). Therefore, it is possible that a common upstream stimulus in hepatocytes and macrophages activates JNK in response to TVX, and that this results in cell death in hepatocytes and increased cytokine release in macrophages. Both of these effects could contribute to liver injury from TVX and, more generally, from drugs associated with IDILI.

The knowledge generated in this model of TVX/LPS-treated RAW cells enhances our understanding of TVX-LPS interaction in the murine model of IDILI. Results from this study identified critical roles for TVX-mediated ERK and JNK signaling in macrophages. The findings in RAW cells are strongly supported by substantial evidence previously generated in vivo.
Trofloxacin Increases LPS-Induced TNF Release in RAW Cells


Address correspondence to: Robert A. Roth, Department of Pharmacology and Toxicology, Center for Integrative Toxicology, Michigan State University, Food Safety and Toxicology Building, 1190 Farm Lane, Room 221, East Lansing, MI 48824. E-mail: roth@msu.edu

References


Buchweitz JP, Ganey PE, and Roth RA (2002) Underlying endotoxemia with increases in TNF and require TNF for hepatotoxicity, the results of this study raise the possibility that common MAPK signaling mechanisms are at play in IDLI reactions.

Authorship Contributions

Participated in research design: Poulsen, Albee, Ganey, Roth. Conducted experiments: Poulsen, Albee. Performed data analysis: Poulsen. Wrote or contributed to the writing of the manuscript: Poulsen, Ganey, Roth.
Trovaflaxacin Potentiation of Lipopolysaccharide-Induced Tumor Necrosis Factor Release from RAW 264.7 cells requires ERK and JNK.

Kyle L. Poulsen, Ryan P. Albee, Patricia E. Ganey and Robert A. Roth

Journal of Pharmacology and Experimental Therapeutics

Supplemental Figure 1. Effect of TVX treatment on TNF mRNA expression in RAW cells after LPS exposure. RNA was isolated from RAW cells after SAL- or LPS-exposure at the indicated times. The RNA was converted to cDNA, and TNF mRNA was quantified by RT-PCR and normalized to β-actin mRNA. Values are means of fold change of VEH/SAL ± SEM, n=6. No significant differences were observed due to TVX pretreatment.
Trovafoxacin Potentiation of Lipopolysaccharide-Induced Tumor Necrosis Factor Release from RAW 264.7 cells requires ERK and JNK.

Kyle L. Poulsen, Ryan P. Albee, Patricia E. Ganey and Robert A. Roth

Journal of Pharmacology and Experimental Therapeutics

Supplemental Figure 2. Lack of effect of LVX treatment on TNF mRNA expression in RAW cells. RNA was isolated from RAW cells after VEH or LVX (300 uM) exposure for 2h, converted to cDNA, and TNF mRNA was quantified by RT-PCR and normalized to β-actin mRNA. Values are means ± SEM, n=3. No significant difference was observed.
Trovafloxacin Potentiation of Lipopolysaccharide-Induced Tumor Necrosis Factor Release from RAW 264.7 cells requires ERK and JNK.

Kyle L. Poulsen, Ryan P. Albee, Patricia E. Ganey and Robert A. Roth

Journal of Pharmacology and Experimental Therapeutics

Supplemental Figure 3. NF-κB binding analysis in TVX/LPS-coexposed RAW cells. Protein extracts were prepared from TVX-pretreated RAW cells at the indicated time following LPS exposure, and p65 subunit binding to the consensus NF-κB response element was assessed by ELISA. Values are mean O.D. @ 450 nm ± SEM, n=3. a - p < 0.05 vs. VEH/SAL within a timepoint, b - p < 0.05 vs. VEH/LPS within a timepoint